NCT06408116 Predicting Esophageal Cancer Borders Using PET-Imaging
| NCT ID | NCT06408116 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University Hospital Heidelberg |
| Condition | Esophagus Cancer, Stage I |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 30 participants in total. It began in 2024-03-01 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study examines the diagnostic precision of endosonography, mpMRI and PET/CT in defining tumor boundaries and tumor spread before and after neoadjuvant therapy and definitive surgery.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus, including AEG I and AEG II tumors in the primary situation * Planned surgical treatment of esophageal carcinoma * Possible staging advantage through FAPI PET/CT diagnostics * Patient information and written consent -\> KI 60% or ECOG 0/1 (at least: self-sufficiency) * Age ≥ 18 years Exclusion Criteria: * Previous radiation therapy in the tumor region * Previous tumor disease with \< 5 years of remission * Surgical therapy is not functionally or technically possible * Distant metastasis * Patient is not capable of giving consent * Concurrent participation in another clinical trial that could affect the results of this trial or the other trial * Illnesses that do not allow the person concerned to assess the nature and scope as well as possible consequences of the clinical study * pregnant or breastfeeding women * Signs that the person taking part is unlikely to comply with the therapy (e.g. unwillingness to cooperate)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06408116 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Esophagus Cancer, Stage I. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06408116 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06408116 currently recruiting?
Yes, NCT06408116 is actively recruiting participants. Contact the research team at christoph.find.@med.uni-heidelberg.de for enrollment information.
Where is the NCT06408116 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT06408116 clinical trial?
NCT06408116 is sponsored by University Hospital Heidelberg. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.